Our approach combines innovative gene editing technologies with an advanced lipid nanoparticle (LNP) delivery system, creating a versatile platform designed to address a wide range of serious diseases. Central to our mission is the development of internal capabilities, including end-to-end manufacturing, to ensure the highest standards of quality and scalability.

Our pipeline covers cardiovascular, metabolic, and rare genetic diseases, with multiple programs already in the clinic:
YOLT-201 (ATTR): advancing towards Phase III clinical trial.
YOLT-101 (HeFH): received dual regulatory clearances in China and the U.S.
YOLT-204 (TDT/SCD): ongoing in IIT clinical trials.
YOLT-203 (PH1): global phase II clinical trial of YOLT-203-PH1 is conducting.

YolTech Therapeutics

Org chart

Teams

Offices